Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Alzheimer’s disease, multiple sclerosis, type-2 diabetes, melanoma and breast cancers, among others.

Pharmaceutical

Olatec Therapeutics

Damaris B. Skouras

Piscitelli Philip

Jeanette Rooney, CPA, CGMA

Cynthia (Dana) Barrow

Mustafa Noor

Joseph St. Laurent

Charles A. Dinarello

The Scientific Advisors at Olatec Therapeutics are tasked with providing expert guidance on the design, development, and implementation of research projects related to NLRP3 antagonist therapeutics. They leverage their extensive knowledge in immunology and pharmacology to help shape clinical strategies, support regulatory submissions, and ensure that the scientific integrity of the company's therapeutic innovations is maintained. By collaborating with cross-functional teams, they aim to advance Olatec’s mission of addressing a wide range of inflammatory diseases.

Scientific Advisors

Leadership Team

Clinical Advisors

Scientific Advisors

About

Team members

Other teams at Olatec Therapeutics

Leadership Team

Clinical Advisors